GoodRx Surges on Novo Nordisk Deal as Hims & Hers Health Faces Setback

GoodRx Holdings (GDRX) shares rallied more than 37% after announcing a partnership with Novo Nordisk (NVO) to offer the pharmaceutical giant's GLP-1 drugs, Ozempic and Wegovy, at $499 per month. The deal comes as Novo Nordisk abruptly ended its collaboration with rival Hims & Hers Health (HIMS), citing concerns over illegal compounding and deceptive marketing practices.

Hims & Hers Health stock fell 2% following the news, compounding its challenges as it now faces potential legal risks. The telehealth platform's loss has become GoodRx's gain, with the latter positioning the agreement as a way to expand access to high-demand medications for underinsured patients.

Novo Nordisk shares ROSE 3.7% on the announcement, reflecting investor confidence in the new distribution channel. The GLP-1 drug market continues to attract intense interest, with pricing and accessibility remaining key battlegrounds for healthcare platforms.